Last reviewed · How we verify
Zavegepant 4 x 25mg enteric coated soft gel capsule — Competitive Intelligence Brief
phase 1
Live · refreshed every 30 min
Target snapshot
Zavegepant 4 x 25mg enteric coated soft gel capsule (zavegepant-4-x-25mg-enteric-coated-soft-gel-capsule) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Zavegepant 4 x 25mg enteric coated soft gel capsule TARGET | zavegepant-4-x-25mg-enteric-coated-soft-gel-capsule | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Zavegepant 4 x 25mg enteric coated soft gel capsule CI watch — RSS
- Zavegepant 4 x 25mg enteric coated soft gel capsule CI watch — Atom
- Zavegepant 4 x 25mg enteric coated soft gel capsule CI watch — JSON
- Zavegepant 4 x 25mg enteric coated soft gel capsule alone — RSS
Cite this brief
Drug Landscape (2026). Zavegepant 4 x 25mg enteric coated soft gel capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/zavegepant-4-x-25mg-enteric-coated-soft-gel-capsule. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab